These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 25663430)

  • 1. Do insurers respond to risk adjustment? A long-term, nationwide analysis from Switzerland.
    von Wyl V; Beck K
    Eur J Health Econ; 2016 Mar; 17(2):171-83. PubMed ID: 25663430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 2018 risk-adjustment reform in the Czech Republic: Introducing Pharmacy-based Cost Groups and strengthening reinsurance.
    Bryndová L; Hroboň P; Tulejová H
    Health Policy; 2019 Aug; 123(8):700-705. PubMed ID: 31196570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re-insurance in the Swiss health insurance market: Fit, power, and balance.
    Schmid CP; Beck K
    Health Policy; 2016 Jul; 120(7):848-55. PubMed ID: 27157115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk Adjustment, Reinsurance Improved Financial Outcomes For Individual Market Insurers With The Highest Claims.
    Jacobs PD; Cohen ML; Keenan P
    Health Aff (Millwood); 2017 Apr; 36(4):755-763. PubMed ID: 28356320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk adjustment in health insurance and its long-term effectiveness.
    Beck K; Trottmann M; Zweifel P
    J Health Econ; 2010 Jul; 29(4):489-98. PubMed ID: 20434784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjusting for risk selection in state health insurance exchanges will be critically important and feasible, but not easy.
    Weiner JP; Trish E; Abrams C; Lemke K
    Health Aff (Millwood); 2012 Feb; 31(2):306-15. PubMed ID: 22323160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The structure and enforcement of health insurance rating reforms.
    Hall MA
    Inquiry; 2000-2001 Winter; 37(4):376-88. PubMed ID: 11252447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing risk selection incentives in health sector reforms.
    Puig-Junoy J
    Int J Health Plann Manage; 1999; 14(4):287-311. PubMed ID: 11184915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heteroscedasticity of residual spending after risk equalization: a potential source of selection incentives in health insurance markets with premium regulation.
    Oskam M; van Kleef RC; Douven R
    Eur J Health Econ; 2024 Apr; 25(3):379-396. PubMed ID: 37162689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs, commitment and locality: a comparison of for-profit and not-for-profit health plans.
    Inquiry; 2004; 41(2):116-29. PubMed ID: 15449428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal cost reimbursement of health insurers to reduce risk selection.
    Kifmann M; Lorenz N
    Health Econ; 2011 May; 20(5):532-52. PubMed ID: 20572200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health insurance exchanges in Switzerland and the Netherlands offer five key lessons for the operations of US exchanges.
    van Ginneken E; Swartz K; Van der Wees P
    Health Aff (Millwood); 2013 Apr; 32(4):744-52. PubMed ID: 23569055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Supplementary insurance as a switching cost for basic health insurance: Empirical results from the Netherlands.
    Willemse-Duijmelinck DMID; van de Ven WPMM; Mosca I
    Health Policy; 2017 Oct; 121(10):1085-1092. PubMed ID: 28855064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk selection and complementary health insurance: the Swiss approach.
    Kifmann M
    Int J Health Care Finance Econ; 2006 Jun; 6(2):151-70. PubMed ID: 16783507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overpaying morbidity adjusters in risk equalization models.
    van Kleef RC; van Vliet RC; van de Ven WP
    Eur J Health Econ; 2016 Sep; 17(7):885-95. PubMed ID: 26420555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capping risk adjustment?
    Eugster P; Sennhauser M; Zweifel P
    J Health Econ; 2010 Jul; 29(4):499-507. PubMed ID: 20462647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can premium differentiation counteract adverse selection in the Dutch supplementary health insurance? A simulation study.
    van Winssen KPM; van Kleef RC; van de Ven WPMM
    Eur J Health Econ; 2018 Jun; 19(5):757-768. PubMed ID: 28762051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new prevention paradox: the trade-off between reducing incentives for risk selection and increasing the incentives for prevention for health insurers.
    Kanters TA; Brouwer WB; van Vliet RC; van Baal PH; Polder JJ
    Soc Sci Med; 2013 Jan; 76(1):150-8. PubMed ID: 23182593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk equalization and voluntary deductibles: a complex interaction.
    van Kleef RC; Beck K; van de Ven WP; van Vliet RC
    J Health Econ; 2008 Mar; 27(2):427-43. PubMed ID: 18178276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards a capitation formula for competing health insurers. An empirical analysis.
    van Vliet RC; van de Ven WP
    Soc Sci Med; 1992 May; 34(9):1035-48. PubMed ID: 1631603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.